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Background: Anticoagulation with vitamin K antagonists such as warfarin has historically been used for the long
term management of patients with thromboembolic disease. However, these agents have a slow onset of action
which requires bridging therapy with heparin and its analogues, which are available only in parenteral route. To
overcome these limitations, new oral anticoagulants such as factor Xa inhibitors and direct thrombin inhibitors have
been developed. The aim of this article is to systematically review the phase 3 clinical trials of new oral
anticoagulants in common medical conditions.
Methods: We searched PubMed (Medline) from January 2007 to February 2013 using “Oral anticoagulants”, “New
oral anticoagulants”, “Randomized controlled trial”, “Novel anticoagulants”, “Apixaban”, “Rivaroxaban”, “Edoxaban”,
“Dabigatran etexilate”, “Dabigatran” and a combination of the above terms. The available evidence from the phase
3 RCTs was summarized on the basis of individual drug and the medical conditions categorized into “atrial
fibrillation”, “acute coronary syndrome”, “orthopedic surgery”, “venous thromboembolism” and “medically
ill patients”.
Results: Apixaban, rivaroxaban and dabigatran have been found to be either non-inferior or superior to enoxaparin
in prophylaxis of venous thromboembolism in knee and hip replacement with similar bleeding risk, superior to
warfarin for stroke prevention in atrial fibrillation with significant reduction in the risk of major bleeding,
non-inferior to aspirin for reducing cardiovascular death and stroke in acute coronary syndrome with significant
increase in the risk of major bleed. Rivaroxaban and dabigatran are also superior to the conventional agents in the
management of symptomatic venous thromboembolism. However, compared to enoxaparin, apixaban and
rivaroxaban use lead to significantly increased bleeding risk in medically ill patients. Additional studies evaluating
the specific reversal agents of these new drugs for the management of life-threatening bleeding or other adverse
effects are necessary.
Conclusion: Considering their pharmacological properties, their efficacy and bleeding complications, the new oral
agents offer a net favourable clinical profile in orthopedic surgery, atrial fibrillation, acute coronary syndrome and
increase the risk of bleeding in critically ill patients. Further studies are necessary to determine the long term safety
and to identify the specific reversal agents of these new drugs.
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Thromboembolic (TE) disease is a common cause of mor-
bidity and mortality. Vitamin K antagonists (VKAs) such
as warfarin are traditionally used for the prolonged man-
agement of thromboembolic disease. However, given the
slow onset of action of these oral medications, a bridging
therapy with either unfractioned or low molecular weight
heparin (LMWH) is routinely used. LMWH is associated
with a reduced rate of adverse effects and have replaced
the use of heparin for several indications.
Since heparin and LMWH are available only for paren-
teral use, continuous attempts have been made to develop
the oral alternatives of these medications. The present art-
icle discusses the new oral anticoagulants. We have sum-
marized the findings of phase 3 trials on the new oral
anticoagulants. A brief overview of the pharmacological
properties of these agents is also presented.What is the necessity of new oral anticoagulants?
Given the need for subcutaneous route of administra-
tion, long term use of LMWH poses a problem. The
new oral anticoagulants specifically target either throm-
bin or factor Xa (Figure 1), whereas warfarin inhibits
synthesis of all vitamin K-dependant clotting factors.
Moreover, in contrast to warfarin, the new oral antico-
agulants produce a predictable anticoagulant effect that
does not require frequent laboratory monitoring in
order to adjust therapy. In addition, along with a rapid
onset and offset of action, these agents have low poten-
tial for dietary interactions. As a result, the new oral
agents are more convenient to administer than warfarin
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Figure 1 Classification of oral anticoagulants in development. * PhaseLiterature search criteria
A review of the literature was carried out from the
PubMed database using the search terms “Oral anticoagu-
lants”, “New oral anticoagulants”, “Randomized controlled
trial”, “Novel anticoagulants”, “Apixaban”, “Rivaroxaban”,
“Edoxaban”, “Dabigatran etexilate” and “Dabigatran” and a
combination of the above terms. The articles were then
manually examined to exclude the duplicate entries. Search
was limited from January 2007 to February 2013. All the
retrieved articles in English language were further searched
to include the phase 3 randomized controlled trials. Obser-
vational studies, phase 1 and phase 2 trials were excluded.
We also excluded personal opinions, editorials, correspon-
dences and perspective articles. Full text versions of the in-
cluded articles were downloaded and evaluated by the
authors to compile a narrative review on the field (Figure 2).
The available evidence from the phase 3 RCTs was summa-
rized on the basis of individual drug and the medical condi-
tions categorized into “atrial fibrillation”, “acute coronary
syndrome”, “orthopedic surgery”, “venous thromboembol-
ism” and “medically ill patients”. Relevant details of the
pharmacokinetic properties of the drugs were added to
complete the drug profile independent of the above men-
tioned literature search.
Apixaban
Apixaban, a highly selective and direct acting, reversible
factor Xa inhibitor, has rapid absorption and a half life of
approximately 12 hours [1-3]. The absorption of this drug
is not affected by food intake and it is eliminated primarily
through fecal (75%) but also through renal (25%) pathway
[4]. The drug undergoes metabolism via cytochrome iso-
form CYP3A4, therefore, concomitant therapy with potentS
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Apixaban**








2 Clinical Trials. ** Phase 3 Clinical Trials.
TOTAL ARTICLES IDENTIFIED
New oral anticoagulants (1104)
Dabigatran AND trial (349)
Apixaban AND trial (174)
Rivaroxaban AND trial (324)
Edoxaban AND trial (54)
CLINICAL TRIALS IDENTIFIED
86
TOTAL NUMBER OF STUDIES 
INCLUDED IN THE REVIEW 




TOTAL NUMBER OF ARTICLES 
EXCLUDED (PHASE 1 TRIALS, 
PHASE 2 TRIALS, REVIEW 
ARTICLES, EDITORIALS) 
58
Figure 2 Inclusion of phase 3 clinical trials for review.
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antibiotics and protease inhibitors is contraindicated in
patients receiving apixaban. In phase 2 clinical trials,
apixaban has been shown to provide effective and pre-
dictable anticoagulation over the doses of 5, 10 or
20 mg/day in the prevention and treatment of venous
thromboembolism [5,6]. Another phase 2 trial demon-
strated the efficacy of two doses of apixaban (2.5 mg
and 5 mg BID) compared with adjusted-dose warfarin
in patients with nonvalvular atrial fibrillation [7].
Medically ill patients
The Apixaban Dosing to Optimize Protection from
Thrombosis (ADOPT) [8] trial randomized 6528 patients
with congestive heart failure, respiratory failure or other
medical disorder with atleast one risk factor for VTE to re-
ceive either apixaban 2.5 mg once daily for 30 days or sub-
cutaneous enoxaparin 40 mg once daily for 6 to 14 days.
However, the extended course of thromboprophylaxis
resulted in significantly increased (p < 0.05) bleeding events
(0.47% patients in the apixaban group vs. 0.19% in the
enoxaparin group; relative risk, 2.58; 95% CI, 1.02 to 7.24).
Orthopedic surgery
Apixaban for the Prevention of Thrombosis-related Events
(ADVANCE) 1 [9] assigned 1599patients to receive 2.5 mg
twice daily apixaban 12 to 24 hours following knee replace-
ment surgery while 1596 patients received enoxaparin30 mg subcutaneously twice daily. The rate of primary effi-
cacy outcome was similar in the 2 groups (9.0% in the
apixaban group compared to 8.8% in the enoxaparin
group). However, the apixaban group was associated with a
significantly (p < 0.05) reduced incidence of major and clin-
ically relevant non-major bleeding episodes (2.9% vs. 4.3%).
The ADVANCE 2 [10] recruited 3057 knee replacement
patients to receive the same apixaban dose or enoxaparin
40 mg daily. This study reported a significantly reduced in-
cidence of total VTE in the apixaban group (15.1%) com-
pared with enoxaparin (24.4%) (p < 0.0001; absolute risk
reduction 9.3% [5.8-12.7]) with a non-significantly (p =
0.09) reduced risk of bleeding (4% vs. 5%).
The Apixaban Dosed Orally Versus Anticoagulation
with Injectable Enoxaparin to Prevent Venous Thrombo-
embolism 3 (ADVANCE-3) trial [11] compared 5407 pa-
tients undergoing hip arthroplasty to receive either 2.5 mg
twice daily apixaban or 40 mg once daily enoxaparin for
5 weeks post-surgery. The primary efficacy outcome oc-
curred in 1.4% patients in the apixaban group compared
with 3.9% in the enoxaparin group (relative risk with
apixaban, 0.36; 95% CI, 0.22 to 0.54; p < 0.001 for both
noninferiority and superiority; absolute risk reduction, 2.5
percentage points; 95% CI, 1.5 to 3.5). The incidence of
major and clinically relevant non-major bleeding events
was similar in the two groups (4.8% in the apixaban group
vs. 5.0% in the enoxaparin group).
Atrial fibrillation
Apixaban for Reduction in Stroke and Other Thrombo-
embolic Events in Atrial Fibrillation (ARISTOTLE) trial
[12] was a comparison between apixaban (5 mg twice
daily) and warfarin (titrated to an INR of 2.0 to 3.0). The
study enrolled a total of 12,801 patients with atrial fibrilla-
tion and at least one risk factor for stroke for a median
duration of 1.8 years. 1.27% patients in the apixaban group
while 1.6% in the warfarin group experienced primary out-
come (hazard ratio with apixaban, 0.79; 95% CI, 0.66 to
0.95; p < 0.001 for noninferiority; p = 0.01 for superiority).
The incidence of hemorrhage in the apixaban group was
0.24% compared to 0.47% in the warfarin group (hazard
ratio, 0.51; 95% CI, 0.35 to 0.75; p < 0.001). The rates of
death in the two groups were 3.52% and 3.94%, respect-
ively (p = 0.047).
The AVERROES [13] (Apixaban Versus Acetylsalicylic
Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients
Who Have Failed or Are Unsuitable for Vitamin K Antag-
onist Treatment) evaluated apixaban 5 mg twice daily
compared with aspirin (81 to 324 mg per day) for a median
duration of 1.1 years in 5599 patients with atrial fibrillation
in which vitamin K antagonist therapy was unsuitable. The
study was terminated earlier because the apixaban group
had significantly reduced primary outcome events (1.6%
per year compared to 3.7% in the aspirin group) (hazard
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Incidence of major bleeding was 1.4% per year in the
apixaban group whereas 1.2% in the aspirin group.
Acute coronary syndrome
To compare apixaban versus standard antiplatelet therapy
in patients with acute coronary syndrome (ACS) with at
least two risk factors for recurrent ischemia, the Apixaban
for Prevention of Acute Ischemic Events 2 (APPRAISE-2)
[14] trial was conducted. It included 7392 patients who
were taking aspirin or aspirin plus clopidogrel after an
ACS. These patients were randomly assigned in a 1:1 ratio
to receive apixaban 5 mg twice daily or matching placebo.
However, this study was terminated prematurely due to
significantly increased bleeding incidence (1.3%) in the
apixaban group compared to 0.5% in the antiplatelet group
(hazard ratio with apixaban, 2.59; 95% CI, 1.50 to 4.46; p =
0.001). The primary outcome of cardiovascular death, myo-
cardial infarction (MI) or ischemic stroke occurred in the
7.5% patients assigned in the apixaban group compared to
7.9% in the placebo group (p = 0.51).
Rivaroxaban
Rivaroxaban is another oral, direct acting, reversible fac-
tor Xa inhibitor with a rapid onset of action and dose-
proportional pharmacokinetics and pharmacodynamics
[15,16]. It has a half-life of up to 12 hours in elderly pa-
tients, and up to 9 hours at steady state in young healthy
subjects [2]. Food does not affect its absorption from the
gastrointestinal tract. It has a dual mode of elimination,
since one-third of the active drug is excreted unchanged
renally while two-thirds of the drug undergoes hepatic
metabolism. Like apixaban, it interacts with potent in-
hibitors of cytochrome P450 enzyme CYP3A4; however,
unlike apixaban, it also interacts with potent inhibitors
of P-glycoprotein, therefore drugs like quinidine are con-
traindicated in rivaroxaban-treated patients [4]. It should
be used cautiously in patients with severely impaired
renal function. It has no effect on the QTc interval [17].
Medically ill patients
In the MAGELLAN (Multicenter, rAndomized, parallel
Group Efficacy and safety study for the prevention of VTE
in hospitalized acutely iLL medical patients comparing
rivaroxabAN with enoxaparin) [18] study, a total of 8101
patients aged ≥ 40 years with acute medical illness were
randomized to receive 40 mg subcutaneous enoxaparin
once a day for 10 ± 4 days and oral placebo for 35 ± 4 days
or subcutaneous placebo for 10 ± 4 days and 10 mg oral
rivaroxaban once daily for 35 ± 4 days for VTE prophylaxis.
A primary efficacy outcome (composite of asymptomatic
proximal or symptomatic venous thromboembolism) oc-
curred in 2.7% of the patients in each group at day 10 (rela-
tive risk with rivaroxaban, 0.97; 95% CI, 0.71 to 1.31; p =0.003 for noninferiority) and in 4.4% of patients receiving
rivaroxaban and in 5.7% of patients receiving enoxaparin
followed by placebo at day 35 (relative risk, 0.77; 95% CI,
0.62 to 0.96; p = 0.02 for superiority). Rivaroxaban demon-
strated more clinically relevant bleeding as compared to
enoxaparin at day 10 (2.8% vs. 1.2%; p < 0.001) and at day
35 (4.1% vs. 1.7%; p < 0.001).Orthopedic surgery
The Regulation of Coagulation in Orthopedic Surgery to
Prevent Deep Venous Thrombosis and Pulmonary Embol-
ism 1 (RECORD 1) [19] trial compared the efficacy and
safety of 10 mg oral rivaroxaban once daily initiated postop-
eratively to 40 mg subcutaneous enoxaparin once daily ini-
tiated preoperatively in the prevention of VTE in 4541
patients undergoing total hip arthroplasty. The primary effi-
cacy outcome occurred in 1.1% patients in the rivaroxaban
group compared with 3.7% in the enoxaparin group (abso-
lute risk reduction, 2.6%; 95% CI, 1.5 to 3.7; p < 0.001).
Major bleeding events occurred in 0.3% patients in the
rivaroxaban group and in 0.1% patients in the enoxaparin
group (p = 0.18).
The RECORD 2 [20] trial compared extended duration
rivaroxaban (31–39 days) to short-term enoxaparin (10–
14 days) in 2509 patients undergoing total hip arthroplasty.
Again, rivaroxaban was associated with a lower incidence
of VTE and all-cause mortality (2% vs. 9.3%; absolute risk
reduction 7.3%, 95% CI, 5.2-9.4; p < 0.0001). The incidence
of major bleeding events was much the same in both
groups (6.6% in the rivaroxaban group vs. 5.5% in the
enoxaparin group; p = 0.25).
The RECORD 3 [21] study recruited 2531 knee replace-
ment patients to receive the same dose of oral rivaroxaban
or subcutaneous enoxaparin once daily. Rivaroxaban was
superior to enoxaparin in preventing VTE and all-cause
mortality 13–17 days after surgery (9.6% vs. 18.9%; abso-
lute risk reduction, 9.2%; 95% CI, 5.9 to 12.4; p < 0.001).
Major bleeding events were similar (0.6% rivaroxaban vs.
0.5% enoxaparin).
In the RECORD 4 [22] trial, 3148 patients undergoing
knee arthroplasty were randomized to receive the same
dose of rivaroxaban once daily and the North American
enoxaparin regimen (2 × 30 mg/d), compared to the
European regimen (1 × 40 mg/d) used in the previous
RECORD trials. This trial also demonstrated that
rivaroxaban had significantly reduced primary outcome
events (6.9% vs. 10.1%; absolute risk reduction 3.19%,
95% CI 0.71-5.67; p = 0.0118) and major bleeding events
were comparable (0.7% rivaroxaban vs. 0.3% enoxaparin;
p = 0.1096). These phase 3 trials showed comparable
safety and superior efficacy of rivaroxaban compared
with enoxaparin for thromboprophylaxis after hip or
knee arthroplasty.
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The Rivaroxaban Once Daily Oral Direct Factor Xa Inhib-
ition Compared with Vitamin K Antagonism for Preven-
tion of Stroke and Embolism Trial in Atrial Fibrillation
(ROCKET AF) [23,24] was conducted in 14,264 patients of
non-valvular atrial fibrillation. The trial suggested that at a
dose of 20 mg (15 mg in patients with creatinine clearance
of 30 to 49 ml/min), the rivaroxaban group was associated
with significantly reduced incidence of stroke or systemic
embolism compared with the warfarin group (hazard ratio
in the rivaroxaban group, 0.79; 95% CI, 0.66 to 0.96; p <
0.001 for noninferiority). Similarly, the incidence of fatal
bleeding (0.2% vs. 0.5%, p = 0.003) and intracranial
hemorrhage (0.5% vs. 0.7%, p = 0.02) was significantly
reduced in the rivaroxaban group compared to warfarin.
Acute coronary syndrome
On the basis of Anti-Xa Therapy to Lower Cardiovascu-
lar Events in Addition to Standard Therapy in Subjects
with Acute Coronary Syndrome–Thrombolysis in Myo-
cardial Infarction 46 (ATLAS ACS–TIMI 46), a phase 2
trial of rivaroxaban versus placebo to determine the
dose of rivaroxaban in ACS patients [25], a phase 3 trial
designated ATLAS ACS 2–TIMI 51 was conducted
[26]. In this trial, 15, 526 patients were randomized to
receive either 2.5 mg or 5 mg placebo twice daily for a
mean duration of 13 months. The trial suggested that
rivaroxaban significantly (p = 0.008) reduced the pri-
mary end point (death from cardiovascular causes, MI
or stroke). However, rivaroxaban increased the risk of
non-fatal major bleeding (2.1% vs. 0.6%, p < 0.001) and
intracranial hemorrhage (0.6% vs. 0.2%, p = 0.009).
Symptomatic venous thromboembolism
After the initial feasibility studies [27,28] the EINSTEIN
clinical trials program was initiated to test the efficacy
of rivaroxaban as a single agent for the management of
symptomatic VTE. The program comprised of 3 trials.
The results of the Acute DVT Study [29] showed that
rivaroxaban (15 mg twice daily for 3 weeks, followed by
20 mg once daily) had non-inferior efficacy compared with
enoxaparin plus vitamin K antagonist therapy in terms of
the primary outcome (recurrent venous thromboembol-
ism) (2.1% events in the rivaroxaban group versus 3.0% in
the control group; p < 0.001).
The Continued Treatment Study (EINSTEIN-Exten-
sion) [29] showed that rivaroxaban had superior effi-
cacy than the control group (1.3% versus 7.1% events;
p = 0.001).
In the Einstein-PE study [30], rivaroxaban was non-
inferior to the standard therapy with enoxaparin and vita-
min K antagonist for the primary efficacy outcome in
patients with acute symptomatic pulmonary embolism
with or without deep-vein thrombosis (2.1% events inthe rivaroxaban group versus 1.8% in the control group;
p = 0.003).Edoxaban
Edoxaban is a rapidly absorbed active drug with a half life
of 9–11 hours [4,31]. An RCT has demonstrated that the
effect of food on the pharmacokinetic properties of the
drug is clinically insignificant [32]. The drug is eliminated
both via kidney (one third) and in feces (two third). A
double blind Phase 2 RCT of Edoxaban versus subcutane-
ous daltaperin has demonstrated significantly reduced in-
cidence (p < 0.001) of venous thromoembolism after
elective total hip replacement at both low (15 and 30 mg)
and higher (60 and 90 mg) doses of edoxaban [33]. Simi-
larly, the drug significantly reduced the incidence of VTE
in patients of total knee arthroplasty when compared with
placebo while the rates of bleeding were similar in both
groups [34]. Another phase 2 study showed that the safety
profiles of 30 and 60 mg qd doses of the drug were similar
when compared with warfarin [35]. The ENGAGE-AF
-TIMI48 is a phase 3 noninferiority design megatrial that
is comparing edoxaban (30 mg or 60 mg once daily) or
warfarin (titrated to an INR of 2.0 to 3.0) in preventing
thromboembolism among 20,500 patients of atrial fibrilla-
tion [36].Dabigatran etexilate
Dabigatran etexilate is an orally active pro-drug which is
rapidly converted to dabigatran by esterase-mediated hy-
drolysis in the plasma and the liver [37]. Dabigatran dir-
ectly and reversibly inhibits both free and fibrin-bound
thrombin, thereby interrupting the coagulation cascade.
The oral bioavailability of this drug is approximately
6%-7%, which is much lower than that of the other three
oral anticoagulants [1,4]. It has a half-life of 14 to
17 hours. Dabigatran is predominately (80%) excreted
unchanged by the kidneys and its plasma levels are in-
creased in patients with renal insufficiency [37,38]. It is
contraindicated in patients with severe renal dysfunc-
tion (creatinine clearance <30 ml/min) [39].
Dabigatran is not metabolized by cytochrome P450 iso-
enzymes. Co-administration of dabigatran with atorvastatin
(a substrate for CYP3A4 and P-glycoprotein) [40], digoxin
(a P-glycoprotein substrate) [41] or diclofenac (a CYP2C9
substrate) [42] did not result in clinically relevant drug in-
teractions. However, dabigatran etexilate (not the active
dabigatran) acts as a substrate for Pglycoprotein. Therefore,
drugs that inhibit P-glycoprotein, such as quinidine, verap-
amil and amiodarone, will increase the plasma levels of
dabigatran [43]. Administration of dabigatran etexilate
with food prolonged the time to peak plasma levels by ap-
proximately 2 hours without significantly affecting overall
exposure [44].
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On the basis of the results of phase 2 studies demon-
strating that dabigatran is effective for the prevention of
venous thromboembolism (VTE), phase 3 studies for
thromboprophylaxis after hip or knee arthroplasty were
conducted. In the RENOVATE I trial [45], 3494 patients
undergoing total hip replacement were randomized to
treatment for 28 to 35 days with 220 mg or 150 mg
dabigatran once daily initiated after surgery, or subcuta-
neous enoxaparin 40 mg once daily, initiated preopera-
tively. The primary efficacy outcome (total VTE or
death) occurred in 6%, 8.6% and 6.7% of patients in the
dabigatran 220 mg, 150 mg and enoxaparin groups, re-
spectively. Risk differences were −0.7% (95% CI, -2.9 to
1 · 6%) and 1.9% (95% CI, −0 · 6 to 4 · 4%) for dabigatran
220 mg and 150 mg, respectively, compared with
enoxaparin. Moreover, the incidence of major bleeding
events did not differ significantly with either dose of
dabigatran compared with enoxaparin (p = 0.44 for
220 mg, p = 0.60 for 150 mg). Similarly, in the RE-
MODEL trial [46] enrolling 2076 patients undergoing
total knee replacement, 6 to 10 days of treatment with
either dose of dabigatran had efficacy similar to that of
enoxaparin (enoxaparin 37.7%; 220 mg dabigatran,
36.4%; 150 mg dabigatran, 40.5%). Also, the incidence of
major bleeding events did not differ significantly be-
tween the three groups (1.3% versus 1.5% and 1.3%,
respectively).
The RENOVATE II trial [47] compared 28 to 35 days of
treatment with dabigatran 220 mg once daily with sub-
cutaneous enoxaparin 40 mg once daily for prevention of
VTE in 2055 patients undergoing total hip arthroplasty. In
this trial, the primary efficacy outcome occurred in 7.7%
of the patients receiving dabigatran versus 8.8% of the pa-
tients receiving enoxaparin. Risk difference was −1.1%
(95% CI, -3.8 to 1.6%); p < 0.0001 for the pre-specified
non-inferiority margin. The rates of primary efficacy
outcome observed in this trial were consistent with
those observed in REVOVATE I [45]. Major bleeding
events occurred in 1.4% of the patients in the dabigatran
group and in 0.9% of the patients in the enoxaparin
group (P = 0.40).
In the RE-MOBILIZE trial [48] of 1896 patients under-
going total knee arthroplasty, the North American
enoxaparin regimen (30 mg BID postoperatively) was used.
Treatment with either dose (220 mg or 150 mg) of
dabigatran for 12 to 15 days was found to be statistically
inferior to enoxaparin treatment for a similar duration
(venous thromboembolism rates of 31% for 220 mg
dabigatran [p = 0.02 vs. enoxaparin], 34% for 150 mg
dabigatran [p < 0.001 vs. enoxaparin], and 25% with
enoxaparin). This suggests that enoxaparin 30 mg twice
daily is substantially more effective than enoxaparin 40 mg
once daily for the prevention of VTE in patientsundergoing knee arthroplasty. However, there were no sig-
nificant differences in the incidence of major bleeding
events (0.6%, 0.6%, and 1.4%, respectively).
Atrial fibrillation
The Randomized Evaluation of Long-term Anticoagulant
Therapy (RE-LY) trial [49] enrolled 18,113 patients with
atrial fibrillation who were at risk for stroke. Two doses of
dabigatran, 110 mg or 150 mg twice daily, administered in
a blinded fashion, were compared with adjusted-dose war-
farin, which was administered in an unblended fashion.
The rate of primary outcome (systemic embolism or
stroke) was 1.69% per year for warfarin, as compared with
1.11% per year for dabigatran at dose of 150 mg twice
daily (relative risk, 0.66; 95% CI, 0.53 to 0.82; p < 0.001 for
superiority) and 1.53% per year for dabigatran at a dose of
110 mg twice daily (relative risk with dabigatran, 0.91; 95%
CI, 0.74 to 1.11; p < 0.001 for noninferiority.) Compared
with warfarin (3.36% per year), however, the risk of major
bleeding was 2.71% per year for dabigatran at a dose of
110 mg (p = 0.003), but similar (3.11% per year) for
dabigatran at a dose of 150 mg (p = 0.31). Both doses of
dabigatran were therefore better than warfarin.
Acute coronary syndrome
In patients with recent ST-elevation or non ST-elevation
MI, dabigatran was given in addition to dual antiplatelet
therapy in a double-blind, placebo-controlled, dose-
escalation phase 2 (RE-DEEM) trial [50]. A total of 1861
patients were randomized to twice daily treatment with
dabigatran 50 mg (n = 369), 75 mg (n = 368), 110 mg (n =
406), 150 mg (n = 347), or placebo (n = 371). This trial
showed that 3.8% of the patients in the placebo group had
an MI, stroke or died compared with dabigatran at differ-
ent doses; 4.6% in patients treated with 50 mg, 4.9% for
75 mg, 3% for 110 mg and 3.5% for those treated with
150 mg dabigatran.
Additionally, the incidence of major or clinically rele-
vant minor bleeding events during the 6-month treat-
ment period increased in a dose-dependent manner with
dabigatran; the hazard ratio was 1.77 for 50 mg, 2.17 for
75 mg, 3.92 for 110 mg and 4.27 for 150 mg dabigatran
compared with placebo.
The RE-LY trial [49] suggested an increased risk of MI
with the use of dabigatran versus warfarin in patients with
atrial fibrillation. In order to evaluate the risk of MI or
ACS with dabigatran, a meta-analysis of seven trials of
dabigatran was conducted [51]. Control agents in the
studies included warfarin, enoxaparin and placebo admin-
istration. The results showed that the risk of MI or ACS
was significantly higher in the 20,000 dabigatran patients
than in the 10,514 control patients (1.19% vs. 0.79%, p =
0.03). The risk of MI or ACS was similar when using re-
vised RE-LY trial results (95% CI, 1.00 to 1.61; p = 0.05).
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In the RE-COVER 1 trial [52], patients with acute ven-
ous thromboembolism were randomized double-blind to
six months of treatment with either dabigatran 150 mg
twice daily or warfarin that was dose-adjusted to achieve
an INR of 2.0 to 3.0 after initial treatment with a paren-
teral anticoagulant. Recurrent venous thromboembolism
or related deaths occurred in 30 of the 1274 patients
(2.4%) in the dabigatran group as compared with 27 of the
1265 patients (2.1%) in the warfarin group (95% CI, −0.8
to 1.5; p < 0.001 for the prespecified noninferiority mar-
gin). The hazard ratio with dabigatran was 1.10 (95% CI,
0.65 to 1.84). Major bleeding episodes in patients assigned
to dabigatran (1.6%) were also at the same rate (1.9%) as
for patients assigned to warfarin (hazard ratio with
dabigatran, 0.82; 95% CI, 0.45 to 1.48).
Conclusion
In this review, we have summarized the evidence from
phase 3 clinical trials pertaining to the efficacy of
apixaban, rivaroxaban, edoxaban and dabigatran in com-
monly encountered clinical conditions such as acute cor-
onary syndrome, atrial fibrillation, symptomatic venous
thromboembolism and orthopedic surgery. Our review
suggests that the new oral anticoagulants represent a
safe promising new class of drugs with potential to re-
place warfarin in the future. As these agents become
more commonly used in clinical practice, it is imperative
for the physicians to be aware of their pharmacological
properties. Also, the future studies should attempt to
identify effective reversal agents to be used in case of an
adverse effect, such as a major bleed.
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